Pharmaceutical Executive
November 01, 2006
Column
0
0
When novartis had a look at its recent M&A activity, it found something unsettling: 70 percent of the deals it had done between 1996 and 2004 hadn't delivered their expected value to shareholders. Many other Big Pharmas are saddled with the same problem: The traditional pharmaceutical business model, by which prescription drug makers scoop up assets or companies similar to their own, is going nowhere fast.
November 01, 2006
Opinion
0
0
Critics of the pharma industry have gotten good at selective reporting. So good, I've started tuning out. But, with a public official pulling similar punches, my ears can't help but perk up.
November 01, 2006
Thought Leader
0
0
The ability to customize small molecules-to make them better, safer, and easier to use-has long been a staple of pharmaceutical development. But until recently, scientists had few options for enhancing biologics. San Diego-based Ambrx wants to change that.
November 01, 2006
Column
0
0
Realistic emotions in campaigns create the kind of conversation a woman would have with a close friend.
November 01, 2006
Executive Profile
0
0
When Arthur Higgins first announced that he was about to take the reins of the healthcare group at Bayer, in 2004, colleagues were surprised.
November 01, 2006
Features
0
0
From hedge clippers to balancing elephants, the 20th annual Rx Club Awards honored a display of ads featuring the most creative concepts from around the world.
November 01, 2006
Washington Report
0
0
Long turnaround on ad reviews adds new complications to the process of developing marketing plans.
November 01, 2006
Features
0
0
Clinical researchers cannot reliably use many of today's electronic health records because of the variability among collection systems.
November 01, 2006
Legal
0
0
When one company purchases another's branded trademarks as keyword search terms, the goal is to lure consumers to the buyer's site.
November 01, 2006
Features
0
0
The Deficit Reduction Act was designed to save the government money on Medicaid. But it also has the potential to change the very way pharma companies conduct business-if they can just figure it out.
November 01, 2006
From the Editor
0
0
The US Department of Justice thinks that "Average Wholesale Price" should mean just what the words say-no more, no less. Why? It's never meant that before.
November 01, 2006
Column
0
0
Hospitals don't want straight-up advertising. If a branded program is going to be integrated into a health-education or health-services platform that's offered directly to a patient's room, it needs to have objective value.
November 01, 2006
Column
0
0
Noncompliance causes 125,000 deaths and more than $100 billion in increased healthcare expenses.